论文部分内容阅读
目的观察延长依那西普给药间隔对强直性脊柱炎(AS)的临床疗效。方法选取该院2011-2013年接受依那西普治疗的AS患者12例,初始治疗依那西普50mg/周,诱导缓解6个月后,每3个月拉长给药间隔,分别为50mg/15d、50mg/30d,采用Bath强直性脊柱炎疾病活动指数(BASDAI)、Bath强直性脊柱炎功能指数(BASFI)、强直性脊柱炎活动指数(ASDAS)及红细胞沉降率(ESR)、C-反应蛋白(CRP)等作为评估指标,持续观察12个月。结果在初始治疗的6个月,各项评估指标均明显下降,差异均有统计学意义(P<0.05),随着给药间隔的延长,BASDAI、BASFI、ASDAS无明显升高,ESR、CRP持续正常。结论延长依那西普给药间隔能够维持AS患者的持续缓解。
Objective To observe the clinical effect of prolonged etanercept interval on ankylosing spondylitis (AS). Methods Twelve patients with AS who received etanercept from 2011 to 2013 in our hospital were enrolled in this study. Initial treatment with etanercept 50 mg / week, 6 months after induction of remission, and the intervals of drug lengthening every 3 months were 50 mg (BASDAI), Bath ankylosing spondylitis index (BASFI), ankylosing spondylitis activity index (ASDAS), and erythrocyte sedimentation rate (ESR) were measured at 15 and 50 mg / Reactive protein (CRP) as an assessment indicator, continuous observation of 12 months. Results At the 6th month of initial treatment, all the indexes of evaluation were significantly decreased (P <0.05). There was no significant increase of BASDAI, BASFI, ASDAS, ESR, CRP Continued normal. Conclusions Prolonged etanercept interval can sustain the sustained remission of AS patients.